HER2CLIMB

February 15, 2021February 15, 2021

Tukysa Combo Approved in EU for Advanced HER2-Positive Breast Cancer

News

Seagen’s Tukysa (tucatinib) has been approved by the European Commission (EC) as part of a triple-combination therapy for people with previously treated advanced or metastatic HER2-positive breast cancer. The EC approved ... Read more

August 17, 2020August 17, 2020

Tukysa Combo Approved in Australia for Advanced HER2-Positive Breast Cancer

News

The Australian Therapeutic Goods Administration (TGA) has approved Seattle Genetics’ Tukysa (tucatinib), when given alongside trastuzumab and Xeloda (capecitabine), for the treatment of patients with advanced inoperable or metastatic HER2-positive breast cancer, who received ... Read more

May 14, 2020May 14, 2020

Tukysa Approved as Combo Therapy for Metastatic HER2-positive Breast Cancer in Switzerland

News

The Swiss Agency for Therapeutic Products (Swissmedic) has approved Seattle Genetics‘ Tukysa, in combination with trastuzumab and Xeloda (capecitabine), for the treatment of patients with metastatic HER2-positive breast cancer. Tukysa is now approved for ... Read more

October 30, 2019

Seattle Genetics’ Tucatinib Extends Survival Outcomes in Metastatic HER2-positive Breast Cancer Patients, Phase 2 Trial Shows

News

People with HER-positive advanced breast cancer who received multiple HER-targeted therapies have significantly better survival outcomes — including overall survival and survival without disease progression — when given a combination ... Read more